Niraparib

Generic Name
Niraparib
Brand Names
Zejula
Drug Type
Small Molecule
Chemical Formula
C19H20N4O
CAS Number
1038915-60-4
Unique Ingredient Identifier
HMC2H89N35
Background

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...

Indication

Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

First Posted Date
2021-02-21
Last Posted Date
2022-04-26
Lead Sponsor
Wake Forest University Health Sciences
Registration Number
NCT04762901

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

First Posted Date
2021-02-21
Last Posted Date
2021-02-21
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
52
Registration Number
NCT04764084
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Niraparib Combined With Radiotherapy in rGBM

Phase 2
Conditions
Recurrent Glioblastoma
Interventions
Drug: Niraparib
First Posted Date
2021-01-20
Last Posted Date
2021-01-20
Lead Sponsor
Tianjin Huanhu Hospital
Target Recruit Count
30
Registration Number
NCT04715620
Locations
🇨🇳

Tianjin Huanhu Hosptal, Tianjin, Tianjin, China

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Phase 2
Recruiting
Conditions
Serous Carcinoma
Endometrial Carcinoma
Interventions
Drug: Niraparib
First Posted Date
2021-01-20
Last Posted Date
2024-01-05
Lead Sponsor
Shandong University
Target Recruit Count
83
Registration Number
NCT04716686
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

First Posted Date
2021-01-08
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
48
Registration Number
NCT04701307
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Phase 2
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: Niraparib
First Posted Date
2020-12-23
Last Posted Date
2022-08-04
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
49
Registration Number
NCT04681469
Locations
🇮🇹

Asst Degli Spedali Civili Di Brescia, Brescia, Italy

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

First Posted Date
2020-12-22
Last Posted Date
2021-08-27
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Target Recruit Count
427
Registration Number
NCT04679064
Locations
🇮🇹

Istituto Tumori della Romagna IRST IRCCS, Meldola, Italy

🇮🇹

Azienda Ospedaliera Spedali Civili, Brescia, Italy

🇮🇹

IEO-Istituto Europeo di Oncologia, Milan, Italy

and more 5 locations

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2020-12-17
Last Posted Date
2024-11-08
Lead Sponsor
University of Washington
Target Recruit Count
18
Registration Number
NCT04673448
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of M4344 in Combination With Niraparib

First Posted Date
2020-12-07
Last Posted Date
2021-06-30
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Registration Number
NCT04655183

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2
Active, not recruiting
Conditions
Ovarian Neoplasms
Breast Neoplasms
Interventions
Drug: Niraparib
First Posted Date
2020-11-23
Last Posted Date
2022-07-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
26
Registration Number
NCT04641247
Locations
🇪🇸

GSK Investigational Site, Marid, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy